A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
Authors
Keywords
-
Journal
LEUKEMIA
Volume 28, Issue 12, Pages 2304-2310
Publisher
Springer Nature
Online
2014-07-16
DOI
10.1038/leu.2014.218
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Journal of Protein Folding Disorders
- (2016) AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
- (2013) A. D. Wechalekar et al. BLOOD
- Renal Transplantation in Systemic Amyloidosis-Importance of Amyloid Fibril Type and Precursor Protein Abundance
- (2012) J. H. Pinney et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
- (2012) J. R. Mikhael et al. BLOOD
- Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
- (2012) C. P. Venner et al. BLOOD
- A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
- (2012) E. Kastritis et al. BLOOD
- Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
- (2012) A. Dispenzieri et al. BLOOD
- Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
- (2012) S. K. Kumar et al. BLOOD
- Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis
- (2012) Stefan Cordes et al. CANCER
- Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease
- (2012) Natalia Tovar et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial
- (2012) V. Sanchorawala et al. HAEMATOLOGICA
- A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis
- (2012) G. Palladini et al. HAEMATOLOGICA
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
- (2012) Giovanni Palladini et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
- (2012) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
- (2012) H Landau et al. LEUKEMIA
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
- (2012) J T Larsen et al. LEUKEMIA
- Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
- (2012) R L Comenzo et al. LEUKEMIA
- Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide
- (2011) Giovanni Palladini et al. ANNALS OF HEMATOLOGY
- Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
- (2011) M. T. Cibeira et al. BLOOD
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
- (2011) D. E. Reece et al. BLOOD
- Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study
- (2011) V. Sanchorawala et al. HAEMATOLOGICA
- Outcome in Renal AL Amyloidosis After Chemotherapy
- (2011) Jennifer H. Pinney et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum transthyretin levels in Swedish TTR V30M carriers
- (2010) Joel Buxbaum et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
- (2010) Efstathios Kastritis et al. JOURNAL OF CLINICAL ONCOLOGY
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
- (2008) A. D. Wechalekar et al. HAEMATOLOGICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now